RPL17P35

Across TCGA pan-cancer cohorts, RPL17P35 RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of RPL17P35’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where RPL17P35 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPL17P35 is over-expressed in tumor, although a few such as THCA and BRCA show the opposite, repressed pattern.

KIRC, THCA, and PRAD are the cancer types where RPL17P35 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL17P35 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	All	+0.042	.006	5	view →
THCA	All	All	−0.026	.022	3	view →
PRAD	All	All	+0.081	<.001	2	view →
BRCA	All	All	−0.063	.021	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

RPL17P35–KIRC

Open the KIRC breakdown →